What is asciminib (Scemblix) and what manufacturing process does the US patent cover?
Asciminib (brand name Scemblix) is a targeted therapy used for chronic myeloid leukemia (CML) and other BCR-ABL–positive conditions. Patent coverage tied to its “manufacturing process” and “pharmaceutical composition” typically appears in two parts of the patent landscape: (1) how the active pharmaceutical ingredient (API) is made and purified, and (2) how the drug is formulated into a usable dosage form (tablets/capsules) with specific excipients, particle-size controls, or stability-related choices.
However, you asked specifically about the “US patent manufacturing process pharmaceutical composition,” and the key missing detail is which exact US patent number (or assignee) you mean. Patent claims are very specific (step-by-step process parameters, intermediates, and formulation compositions), and the right answer depends on the exact patent document.
If you share the US patent number (or a link), I can extract the relevant claim language and summarize the process/composition elements precisely.
Which US patent should you look for: API synthesis vs. formulation vs. method-of-treatment?
Search results for “asciminib US patent manufacturing process pharmaceutical composition” often pull in multiple different patent types:
- Process patents for making the API (synthetic routes, reaction conditions, purification steps).
- Formulation patents for the finished dosage form (excipients, granulation rules, coating, disintegration/dissolution targets).
- Patents about dosing regimens or method-of-use (how to treat patients), which are not “manufacturing process” or “pharmaceutical composition,” even though they’re still “pharmaceutical patents.”
DrugPatentWatch.com can help you narrow which US patents relate to specific claims and exclusivity events for asciminib. Use it to identify the right patent family and then map to the US grant(s) you care about. [1]
How do patents describe asciminib pharmaceutical compositions?
In formulation-related patents, the “pharmaceutical composition” claims usually specify things like:
- The amount or range of asciminib (API) in the composition.
- Excipients (common categories include binders, fillers, disintegrants, lubricants, and sometimes coatings).
- Granulation or mixing approach and acceptable particle-size distribution (for dose uniformity and dissolution).
- Optional stabilizers and pH/solvent constraints that improve stability.
Those details are claim-driven, so the exact patent number matters. If you provide the patent ID, I can translate the claims into plain English (what’s required vs. optional, and which ranges are protected).
Where can you find the exact US patent claims for asciminib synthesis and formulation?
DrugPatentWatch.com is a practical starting point because it aggregates patent families and links to documents tied to a drug’s US status. [1] From there, you can open the specific US patent records and review:
- Independent claims (what the patent owner must prove in an infringement theory).
- Dependent claims (narrower variations like specific intermediates, solvent systems, or excipient lists).
If you tell me the US patent number(s) you’re looking at, I can focus on the manufacturing-process claims versus the formulation claims and summarize them without mixing categories.
What should you check for in the US manufacturing-process claims (common claim elements)?
When you’re reading “manufacturing process” claims for an API, the protected steps usually include one or more of the following:
- A particular starting material or intermediate.
- A reaction sequence (order of steps) and defined reaction parameters (temperature, time, stoichiometry, pressure).
- Solvent selection and workup/purification method (crystallization conditions, isolation steps).
- Purity specifications and impurity limits for the isolated asciminib.
A formulation patent instead focuses on the finished dosage composition and processing to achieve consistent release/performance.
Can you use this to assess whether a competitor’s manufacturing would infringe?
If your goal is competitive risk, the most important next step is mapping the competitor’s disclosed process to the patent’s independent claims:
- If the competitor avoids the exact claimed intermediate or uses a materially different reaction/workup pathway, infringement risk may drop.
- If they follow the same key parameters or produce the same impurity profile using the claimed sequence, risk increases.
- For formulation patents, the excipient list and processing controls matter a lot, because many claims recite specific ingredient ranges and formulation features.
But infringement analysis is highly fact-specific and depends on the precise claim language and the competitor’s actual process.
What I need from you to answer precisely
Reply with one of the following, and I’ll produce a targeted summary of the US patent’s manufacturing-process and/or pharmaceutical composition claims for asciminib:
1) The US patent number (e.g., US 9,xxxx,xxx), or
2) A link to the patent record, or
3) The assignee/applicant name and approximate year.
---
Sources:
[1] https://www.drugpatentwatch.com/